NeuroGenomeX, Inc. Announces $150,000 Grant from Epilepsy Research Foundation
November 2009, Madison, WI -- NeuroGenomeX, Inc. announced today that its clinical collaborator – Dr. Nathan Fountain of the University of Virginia, had received a $150,000 grant from the Epilepsy Research Foundation to support the pre-clinical and clinical development of NeuroGenomeX's lead compound, 2-deoxy-D-glucose (2DG), for the reduction of epileptic seizures in patients with intractable epilepsy.
"The Epilepsy Research Foundation grant will directly support our anticipated Phase Ib study in epilepsy patients in 2014", said Dr. Thomas Sutula, CSO and founder of NeuroGenomeX. "We are appreciative that the Foundation has again chosen to support the continuing development of 2DG as a novel treatment for epilepsy."
NeuroGenomeX's Dr. Sutula was previously the recipient of a $100,000 investment from the Epilepsy Research Foundation in 2006 for earlier lead development efforts on 2DG. The Epilepsy Research Foundation's New Therapy-Commercialization Grant Program aims to "drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. The Foundation funds innovative senior level research projects led by the nation's leading scientists with the potential to discover new treatment options and ultimately a cure."